Literature DB >> 25441109

Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.

Münci Yağcı1, Fatih Karakaya2, Elif Suyanı2, Rauf Haznedar2.   

Abstract

BACKGROUND: The aim of this study was to investigate the prognostic effect of serum free light chain (sFLC) response after 2 cycles of first-line chemotherapy (CT) in multiple myeloma (MM) patients.
MATERIALS AND METHODS: The data of 78 newly diagnosed MM patients who had sFLC levels at diagnosis and after 2 cycles of first-line CT were included in the study. The prognostic effect of sFLCs were evaluated with normalization of sFLC κ/λ ratio after 2 cycles of CT and involved/uninvolved (i/u) sFLCs.
RESULTS: At the end of follow-up the probability of overall survival (OS) was 95.7% versus 68.5% in patients with and without normalized sFLC κ/λ ratio, respectively (P = .072). The probability of OS with i/u sFLC assessment was 97.4% versus 55.8% with regard to i/u sFLC ≤ 10 and > 10, respectively (P = .001). In univariate and multivariate analysis including sFLC ratio, age, sex, and International Staging System, i/u sFLC ratio > 10 after 2 cycles of CT was identified as an independent risk factor for OS (P = .015; hazard ratio [HR], 13.2; 95% confidence interval [CI], 1.668-104.65 vs. P = .011; HR, 15.17; 95% CI, 1.85-123.89).
CONCLUSION: Early response assessment in terms of sFLC after 2 courses of induction CT seems to have a prognostic effect in MM patients. The methodology and timing of the evaluation based on sFLCs needs to be validated in prospective studies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multiple myeloma; Overall survival (OS); Response; Therapy; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25441109     DOI: 10.1016/j.clml.2014.08.007

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  2 in total

1.  Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).

Authors:  Tanja Holzhey; Wolfram Pönisch; Song-Yau Wang; Madlen Holzvogt; Bruno Holzvogt; Marc Andrea; Thomas Zehrfeld; Doreen Hammerschmidt; Franz Albert Hoffmann; Cornelia Becker; Andreas Schwarzer; Maik Schwarz; Uta Schönfelder-Fricke; Thomas Edelmann; Leanthe Braunert; Georg-Nikolaus Franke; Madlen Jentzsch; Sebastian Schwind; Markus Bill; Juliane Grimm; Yvonne Remane; Uwe Platzbecker; Markus Scholz
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-12       Impact factor: 4.553

2.  Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma.

Authors:  Rony Benson; Sreejith G Nair; Geetha Narayanan
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.